Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tapentadol 25-mg TRF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose |
| 002 | EXPERIMENTAL | tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose |
| Name | Type | Description |
|---|---|---|
| tapentadol (CG5503) ER 25-mg TRF | DRUG | 50 mg TRF single oral dose |
| tapentadol (CG5503) ER 50-mg TRF | DRUG | 50 mg TRF single oral dose |
Inclusion Criteria: * Japanese participants who have resided outside of Japan for no more than 5 years and whose parents and maternal and paternal grandparents are Japanese, as determined by participant's verbal report * Deemed healthy on the basis of prestudy physical examination, medical history ...
Tapentadol 25-mg TRF is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its bioequivalence. The drug is not approved and remains under investigation.
Tapentadol 25-mg TRF is being developed by Johnson & Johnson, traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research on this small molecule drug candidate.
Tapentadol 25-mg TRF is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities.
Tapentadol 25-mg TRF has one completed clinical trial, NCT01273506, which studied the bioequivalence of a 50-mg dose administered as two 25-mg tablets compared to one 50-mg tablet. The trial enrolled 30 healthy male volunteers.
Tapentadol 25-mg TRF is associated with the code name CG5503, as referenced in the clinical trial NCT01273506. The trial title mentions tapentadol (CG5503), indicating these names refer to the same drug candidate.